Test Your Knowledge

Quiz: Is Paclitaxel or Capivasertib-Paclitaxel Combo Superior for Metastatic TNBC?

12/23/2020

Recent News

News

Tegafur-Uracil Maintenance Did Not Improve Survival for Patients With Locally Advanced Cervical Cancer

04/15/2025

Stephanie Holland

According to results from the phase 3 GOTIC-002 trial, low-dose tegafur-uracil maintenance therapy did not improve survival among patients with locally advanced cervical cancer.

According to results from the...

04/15/2025

Oncology

News

First-Line Durvalumab Plus Platinum-Etoposide for Patients With Extensive-Stage Small Cell Lung Cancer

04/14/2025

Stephanie Holland

According to final efficacy and safety results from the phase 3b LUMINANCE trial, first-line durvalumab plus platinum-etoposide demonstrated promise among patients with extensive-stage small cell lung cancer.

According to final efficacy and...

04/14/2025

Oncology

News

Tilsotolimod Plus Ipilimumab Fails to Significantly Improve Outcomes for Patients With Advanced Refractory Melanoma

04/11/2025

Stephanie Holland

According to results from the phase 3 ILLUMINATE-301 study, the addition of tilsotolimod to ipilimumab did not significantly improve outcomes among patients with advanced refractory melanoma.

According to results from the...

04/11/2025

Oncology

News

Cytokine and Chemokines as Predictive Biomarkers of CAR-T Therapy Outcomes in Large B-Cell Lymphoma

04/11/2025

Emily Estrada

Plasma cytokines and chemokine levels may be used as predictive biomarkers of CAR-T therapy response and toxicity among patients with large B-cell lymphoma.

Plasma cytokines and chemokine...

04/11/2025

Oncology

News

The Potential of Targeting NRG1 for Esophageal Squamous Cell Carcinoma

04/10/2025

Allison Casey

Targeting NRG1 may present a potential treatment strategy for esophageal squamous cell carcinoma.

Targeting NRG1 may present a...

04/10/2025

Oncology

News

First-Line Cemiplimab Demonstrates Long-Term Efficacy Among Patients With Advanced Non-Small Cell Lung Cancer With PD-L1 ≥ 50%

04/09/2025

Stephanie Holland

According to 5-year follow-up results from the phase 3 EMPOWER-Lung 1 trial, first-line cemiplimab demonstrated continued efficacy compared to chemotherapy among patients with advanced non-small cell lung cancer with PD-L1 expression ≥ 50%.

According to 5-year follow-up...

04/09/2025

Oncology

News

Odronextamab Demonstrates Durability and Safety for Relapsed/Refractory DLBCL

04/09/2025

Emily Estrada

Treatment for relapsed/refractory diffuse large B-cell lymphoma with odronextamab demonstrated a manageable safety profile and durable responses among patients previously treated with 2 lines of therapy.

Treatment for...

04/09/2025

Oncology

News

Long-Term Real-World Efficacy of CPX-351 Therapy for Patients With High-Risk AML

04/09/2025

Emily Estrada

In a long-term, real-world analysis, CPX-351 induction therapy was significantly associated with achievement of measurable residual disease status, which was correlated with improved overall survival among patients with high-risk AML.

In a long-term, real-world...

04/09/2025

Oncology

FDA Approval

FDA Approves Nivolumab Plus Ipilimumab for Unresectable/Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer

04/08/2025

Stephanie Holland

Based on results from the CHECKMATE-8HW trial, the FDA has approved nivolumab plus ipilimumab for patients 12 years of age and older with unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal...

Based on results from the...

04/08/2025

Oncology

News

First-Line Pembrolizumab With or Without Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

04/08/2025

Stephanie Holland

According to long-term follow up results from the phase 3 KEYNOTE-048 study, first-line pembrolizumab with or without chemotherapy demonstrated long-term survival benefit among patients with recurrent or metastatic head and neck squamous cell...

According to long-term follow up...

04/08/2025

Oncology